Belimumab

Definition

A fully human IgG1 monoclonal antibody directed against B-Lymphocyte stimulator protein (BlyS or TNFSF13B) with potential immunomodulating activity. Belimumab specifically recognizes and inhibits the biological activity of BlyS, thereby preventing the binding of BlyS to B-lymphocytes. This inhibits the maturation of B-lymphocytes and may induce apoptosis in B-lymphocytes. In addition, it may decrease B-lymphocyte proliferation and/or survival. BlyS, a member of TNF family supporting B-lymphocyte maturation and survival, has been implicated in the pathogenesis of autoimmune diseases and B-lymphocyte malignancies.

Also known as BELIMUMAB, Benlysta, Immunoglobulin G1, anti-(Human Cytokine BAFF) (Human Monoclonal LymphoStat-B Heavy Chain), Disulfide with Human Monoclonal LymphoStat-B lambda-chain, Dimer, LymphoStat-B — per NCIT

Also identified as

• ATC L04AG04 per RXNORM
• NCIT NCIT:C91385 per NCIT
• SCTID 449043000 per RXNORM
• SCTID 704193005 per RXNORM
• UNII 73B0K5S26A per RXNORM

Indications